PARADIGM Mentors

Pharmacogenomics

Julie A Johnson

Julie A Johnson Pharm.D.

Dean & Distinguished Professor
Department: Dean's Office
Phone: (352) 273-6309
Mailing Address:
PO Box 100484
GAINESVILLE FL 32610
Physical Address:
1225 CENTER DR
HPNP 4332
GAINESVILLE FL 326103007

Julie A. Johnson, Pharm.D., is dean of the University of Florida College of Pharmacy and distinguished professor of Pharmacy and Medicine. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the UT Health Science Center at San Antonio. She completed a post-doctoral fellowship in cardiovascular pharmacology/pharmacokinetics at Ohio State.

Johnson’s research focuses on cardiovascular pharmacogenomics and genomic medicine implementation. She is an internationally-recognized leader in pharmacogenomics and genomic medicine, with over 300 peer reviewed publications and nearly $50 million in research funding as principal investigator. In 2015, 2016, 2017 she was named a Thomson Reuters (now Clarivate Analytics) Highly Cited Scientist in Pharmacology and Toxicology, and in 2018 in the Cross Discipline category, indicating she is in the top 1% of the most highly cited scientists in the field globally.

Johnson has served on the Nonprescription Drugs Advisory Committee of the FDA, the XNDA Study Section at NIH, and in numerous scientific capacities with NIH’s NHLBI. She has had leadership roles in the American College of Clinical Pharmacy (ACCP), the American Heart Association (AHA), and the American Society of Clinical Pharmacology and Therapeutics (ASCPT), for which she completed her term as President in 2017. She is an elected fellow of the ACCP, the AHA and the American College of Clinical Pharmacology (ACCP-Pharmacology). Johnson was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other awards including teaching awards from both the University of Tennessee (1996) and the University of Florida (2001); the Ohio State University Alumni Association William Oxley Thompson Award for early career achievement (1997), Leon I Goldberg Young Investigator Award from the ASCPT (2004), Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award (2009) and Russell R Miller Award for Contributions to the Literature (2010), both from ACCP, the Southeastern Universities Research Association Distinguished Scientist Award (2015); AACP Volwiler Research Achievement Award (2016), the ACCP-Pharmacology Distinguished Scientist Award (2019), the ACCP Paul Parker Medal (2019), elected fellow of the American Association for the Advancement of Science (2020), the Rawls Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology and Therapeutics (2021), and the Precision Medicine World Conference Luminary Award recipient (2021), among others.

Accomplishments:
  • Luminary Award
    2021 · Precision Medicine World Conference
  • Rawls Palmer Progress in Medicine Award
    2021 · American Society for Clinical Pharmacology and Therapeutics
  • Elected Fellow
    2020 · American Association for the Advancement of Science
  • Distinguished Investigator Award
    2019 · American College of Clinical Pharmacology
  • Paul Parker Medal
    2019 · American College of Clinical Pharmacy
  • Volwiler Research Achievement Award
    2016 · American Association of Colleges of Pharmacy
  • Highly Cited Scientist
    2015-2018 · Clarivate Analytics
  • Distinguished Scientist Award
    2015 · Southeastern Universities Research Associate
  • Elected Member
    2014 · National Academy of Medicine
  • Honorary Fellow Award
    2014 · American College of Clinical Pharmacology
  • Russell Miller Award for Contribution to the Literature
    2010 · American College of Clinical Pharmacy
  • Fellow
    2009 · American Heart Association; Functional Genomics and Translational Biology Council
  • Therapeutic Frontiers Award
    2009 · American College of Clinical Pharmacy
  • Paul Dawson Biotechnology Research Award
    2007 · American Association of Colleges of Pharmacy
  • Leon I. Goldberg Young Investigator Award
    2004 · American Society for Clinical Pharmacology and Therapeutics
  • William Oxley Thompson Alumni Award
    1997 · The Ohio State University
  • Fellow
    1996 · American College of Clinical Pharmacy
Publications:
Grants:
  • Dec 2021 ACTIVE
    Impact of CYP2D6 genotypes and inhibitors on opioid therapy in patients with pain
    AMER COL OF CLINICAL PHAR · Other
  • Sep 2021 ACTIVE
    Warfarin Pharmacogenetics at UF Health
    UF HEALTH SHANDS HOSPITAL · Co-Investigator
  • Jan 2020 – Dec 2021
    Personalizing thiazide therapy through clinical and microRNA biomarkers of response to thiazides
    AMER HEART ASSOCIATION · Other
  • Sep 2018 ACTIVE
    Sparking Advancements in Genomic Medicine?
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Jan 2018 ACTIVE
    Training Program for Applied Research and Development in Genomic Medicine
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Jul 2016 – Sep 2020
    A stem cell tactic to promote personalized medicine
    NATL INST OF HLTH NIGMS · Project Manager
  • Jul 2016 – Jun 2018
    A Stem Cell Tactic to Promote Personalized Medicine in Hypertension
    AMER HEART ASSOCIATION · Faculty
  • Oct 2015 – Mar 2019
    OneFlorida Clinical Research Consortium Phase II
    PATIENT-CENTERED OUTCOMES RES INST · Project Manager
  • Jul 2014 – Dec 2015
    Using Different OMICS for the Identification of Novel Biomarkers of Blood Pressure Response to Antihypertensive Drugs
    AMER HEART ASSOCIATION · Principal Investigator
  • Jun 2013 – Sep 2018
    Genomic Medicine Implementation: The Personalized Medicine Program
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Mar 2011 – Feb 2016
    Secondary Prevention of Subcortical Stroke Prevention Genetics Substudy Timing
    NATL INST OF HLTH NINDS · Principal Investigator
  • Aug 2010 – Jul 2017
    Pharmacogenomic Evaluation of Antihypertensive Responses.
    NATL INST OF HLTH NIGMS · Principal Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Project Manager
Patents:
  • Published May 2009
    Use of Genetic Determinants in Cardiovascular Risk Assessment
    #US 2010-0021903-A1
  • Published August 2007
    B-Blocker Pharmacogenetics in Heart Failure
    #US-2008-0269346-A1
  • Published July 2003
    Beta-Adrenoceptor Genetic Polymorphisms and Obesity
    #US-2004-0033524
  • Published February 2002
    Methods of Diagnosing Obesity and Products Related Thereto
    #US-2002-0187491
Education:
  • 1987-1989
    Postdoctoral Fellowship in Pharmacokinetics/Clinical Pharmacology
    The Ohio State University
  • 1987
    Pharm.D.
    The University of Texas at Austin and The University of Texas Health Science Center at San Antonio
  • 1985
    B.S.
    The Ohio State University
Stephen Kimmel

Stephen Kimmel

Dean’s Professor and Chair
Department: Department of Epidemiology
Phone: (352) 273-5468
Mailing Address:
PO Box 100231
GAINESVILLE FL 32610

Stephen Kimmel, MD, MSCE, is a graduate of Princeton University and New York University School of Medicine. He completed his internal medicine training at Harvard’s Brigham and Women’s Hospital and his cardiology fellowship at the University of Pennsylvania. He has a Master of Science in epidemiology from the Perelman School of Medicine at the University of Pennsylvania. His research, which has been funded continuously for the past 26 years, focuses on improving the use of existing medical therapies, particularly related to genetic epidemiology, adherence, and patient-centered outcomes. His most recent work focuses on novel methods of prediction of outcomes among patients in order to improve patient selection for surgical procedures and lung transplantation. He has served as principal investigator on numerous federal grants, including five R01s, a K24, a large NHLBI N01, a PCORI grant, and a U01 grant. He teaches courses in epidemiology and has also been instrumental in the development and growth of several graduate programs in epidemiology.

Publications:
Grants:
  • Jul 2022 ACTIVE
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Faculty
  • Jul 2022 ACTIVE
    Social Determinants Underlying Disparities in Heart Failure Treatment and Outcomes
    PHARMA RES AND MANUFACTURERS OF AMERICA · Co-Investigator
  • Nov 2021 ACTIVE
    Implementation Strategies for Monitoring Adherence in Real Time (iSMART)
    UNIV OF PENNSYLVANIA · Principal Investigator
  • Sep 2021 ACTIVE
    Alcohol-Associated Syndemic and Microbiome Evaluation and Targeted Treatment in Persons Living with HIV
    NATL INST OF HLTH NIAAA · Other
  • Jul 2021 ACTIVE
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Other
  • Feb 2021 ACTIVE
    Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
    UNIV OF PENNSYLVANIA · Principal Investigator
  • Jan 2021 – Aug 2021
    A general framework to account for outcome reporting bias with systematic reviews
    UNIV OF PENNSYLVANIA · Principal Investigator
  • Jan 2021 – May 2022
    Enhancing the Utility of the Trend-in-Trend Research Design
    UNIV OF PENNSYLVANIA · Principal Investigator
  • Jan 2021 – May 2022
    Digital Phenotyping and Cardiovascular Health
    UNIV OF PENNSYLVANIA · Principal Investigator
  • Dec 2020 ACTIVE
    Dynamic Prediction Modeling to Improve Clinical Predictions
    NATL INST OF HLTH NHLBI · Principal Investigator
  • Aug 2020 – Sep 2021
    The External Exposome and COVID-19 Severity
    NATL INST OF HLTH NIEHS · Project Manager
  • Jan 2018 ACTIVE
    Training Program for Applied Research and Development in Genomic Medicine
    NATL INST OF HLTH NHGRI · Principal Investigator
Larisa H Cavallari

Larisa H Cavallari Pharm.D., BCPS, FCCP

Professor And Debbie DeSantis Term Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-8245
Mailing Address:
PO Box 100486
GAINESVILLE FL 32610
Physical Address:
1600 SW ARCHER RD
HSC PG-22A
GAINESVILLE FL 326103003

Dr. Cavallari received her B.S. Pharmacy and Pharm.D. degrees from the University of Georgia. She then completed a Pharmacy Practice Residency at the Veterans Affairs Medical Center in Memphis, Tennessee and a fellowship in Cardiovascular Pharmacogenomics at the University of Florida. Dr. Cavallari accepted a position as an Assistant Professor of Pharmacy Practice at the University of Illinois at Chicago after completing her training and was promoted to Associate Professor in 2009. While at UIC, she directed efforts to implement genotype-guided warfarin dosing for all patients newly starting warfarin during hospitalization. Dr. Cavallari joined the University of Florida Department of Pharmacotherapy and Translational Research as an Associate Professor in April, 2014, where she serves as director of the Center for Pharmacogenomics and Precision Medicine. She also serves as Director of the UF Health Precision Medicine Program. In 2021, she was promoted to professor. Her research involves discovery and clinical translation of genetic variants related to drug response and has been funded by the NIH, FDA, American Heart Association, and other awards.

Dr. Cavallari has served on both NIH and American Heart Association grant review committees and is a Board Certified Pharmacotherapy Specialist, Fellow of the American College of Clinical Pharmacy, former Chair of the American College of Clinical Pharmacy Research Institute, and Editorial Board Member for the Lexi-Comp pharmacogenetics series.

Accomplishments:
  • Elected Regent
    2019 · American College of Clinical Pharmacy
  • Elected Trustee
    2013-2016 · Research Institute, American College of Clinical Pharmacy
  • Kenneth F. Finger Fellow Alumni Lecturer Award
    2009 · University of Florida
  • Best Paper
    2009 · International Congress on Clinical Pharmacy
  • Fellow
    2008 · American College of Clinical Pharmacy
  • Hans Vahlteich Research Award
    2007 · University of Illinois at Chicago
  • Faculty New Investigator
    2004 · American Association of Colleges of Pharmacy-American Foundation for Pharmaceutical Education Pharmacy
  • Annual Meeting Best Student, Resident, Fellow Paper Award
    2000 · American College of Clinical Pharmacy
  • Kenneth F. Finger Memorial Award for Excellence in Clinical Pharmacy Research
    2000 · University of Florida
  • American Foundation for Pharmaceutical Education for the Biomedical Research Sciences Fellow
    1999-2000 · University of Florida
Publications:
Grants:
  • Sep 2021 ACTIVE
    Preemptive pharmacogenetic testing in medically underserved populations
    NATL INST OF HLTH NHGRI · Co-Investigator
  • Sep 2021 ACTIVE
    Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis
    NATL INST OF HLTH NINDS · Co-Investigator
  • Aug 2021 ACTIVE
    Leveraging the Microbiome, Local Admixture, and Machine Learning to Optimize Anticoagulant Pharmacogenomics in Medically Underserved Patients
    UNIVERSITY OF ARIZONA · Principal Investigator
  • Aug 2020 – Jan 2022
    Identifying Predictors of Spironolactone Response in Patients with Heart Failure with Preserved Ejection Fraction
    NATL INST OF HLTH NHLBI · Other
  • Jul 2020 ACTIVE
    Precision antiplatelet therapy after percutaneous coronary intervention
    NATL INST OF HLTH NHLBI · Principal Investigator
  • Sep 2018 ACTIVE
    Sparking Advancements in Genomic Medicine?
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Apr 2018 – Jul 2019
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Project Manager
  • Apr 2018 – Sep 2019
    Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery
    UF HEALTH SHANDS HOSPITAL · Principal Investigator
  • Jan 2018 ACTIVE
    Training Program for Applied Research and Development in Genomic Medicine
    NATL INST OF HLTH NHGRI · Other
  • Apr 2017 – Jun 2021
    OoR CTSI Institutional Matching Support
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Jun 2016 – Oct 2018
    Development and analytic validation of a customized pharmacogenomics panel
    CANON BIOMEDICAL INC · Principal Investigator
  • Sep 2015 – Aug 2016
    2015 Mallinckrodt Research Fellowship Award
    *MALLINCKRODT PHARMACEUTICALS-Bankrupt · Principal Investigator
  • Sep 2014 – Feb 2019
    Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs
    US FOOD AND DRUG ADMN · Principal Investigator
Education:
  • 1997
    Doctor of Pharmacy
    University of Georgia
Michael J Clare-Salzler

Michael J Clare-Salzler M.D.

Professor Emeritus
Department: MD-PATHOLOGY
Phone: (352) 339-3618
Mailing Address:
PO Box 100275
GAINESVILLE FL 32610
Physical Address:
M649
GAINESVILLE FL 326110001

Michael J. Clare-Salzler, MD, is a professor of medicine who received his medical degree and internal medicine training from the State University of New York at Buffalo. He began his clinical endocrinology and immunology research career at the University of California in Los Angeles, where he studied the immunopathogenesis of type 1 diabetes. 

Dr. Clare-Salzler maintains an active practice in endocrinology, treating patients with diabetes and other endocrine diseases. 

Certifications:
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine
Specialties:
  • Pathology, Immunology and Laboratory Medicine
Clinical Interests:
  • Diabetes
  • Diabetes diet – type 1
  • Diabetes education
  • Diabetes – resources
  • Pheochromocytoma
  • Thyroid cancer
  • Thyroid diseases
  • Thyroid nodule
  • Type 1 diabetes
  • Type 2 diabetes
Publications:
Grants:
  • Sep 2018 ACTIVE
    A 3D Tissue Map of the Human Lymphatic System
    NATL INST OF HLTH NIAID · Project Manager
  • Jun 2013 – Sep 2018
    Genomic Medicine Implementation: The Personalized Medicine Program
    NATL INST OF HLTH NHGRI · Project Manager
  • May 2013 – Jun 2018
    Immune Function and the Progression to Type 1 Diabetes
    NATL INST OF HLTH NIAID · Project Manager
  • Sep 2012 – Aug 2016
    The JDRF nPOD Viral Work Group: nPOD V
    JDRF · Project Manager
  • Jan 2012 – Mar 2017
    Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery ofInsulin Peptide, Vitamin D3, TGF-b1 and GM-CSF for Type-1 Diabetes
    NATL INST OF HLTH · Project Manager
  • Jan 2010 – Jan 2021
    UFFChandler Stetson Professorship Experimental Pathology
    UF FOUNDATION · Principal Investigator
  • Jul 2006 – Dec 2020
    21st Century Research & Economic Development Investment Program (REDIP)
    STATE UNIV SYS OF FL BOARD OF GOVERNORS · Project Manager
Patents:
  • Issued April 2021
    Particle-Based Vaccine for Induction of Specific Tolerance (CON 13603)
    #10,987,314
  • Issued July 2018
    Antigen-Specific, Tolerance-Inducing Microparticles and Uses Thereof
    #10,016,371
  • Published July 2009
    Materials and Methods For The Detection, Prevention and Treatment of Autoimmune Disease
    #US-2010-0178652-A1
  • Issued October 2005
    Materials And Methods For Detection And Treatment Of Immune System Dysfunctions (DIV)
    #6,953,578
  • Published August 2003
    Cox-2 Mediated Altered Prostaglandin Balance in Diabetes Complications
    #US-2004-0121489-A1
  • Published April 2003
    Methods and Compositions for Expressing a Nucleic Acid in a Dendritic Cell
    #US-2004-0072351-A1
  • Issued April 2001
    Materials And Methods For Detection And Treatment Of Immune System Dysfunction (DIV)
    #6,218,133
  • Issued January 2001
    Materials And Methods For Detection And Treatment Of Immune System Dysfunctions
    #6,168,792
  • Issued August 1999
    Materials and Methods for Detection and Treatment of Immune System Dysfunctions.
    #5,939,069
Education:
  • 1988
    Other Program – Endocrinology, Diabetes and Metabolism
    University of California, Los Angeles
  • 1982
    Residency – Internal Medicine
    State University of New York
  • 1980
    Internship- Internal Medicine
    State University of New York
  • 1979
    Medical Degree
    SUNY at Buffalo
Rhonda M Cooper-DeHoff

Rhonda M Cooper-DeHoff Pharm.D., M.S., FAHA, FACC, FCCP

Associate Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-6184
Mailing Address:
PO Box 115500
GAINESVILLE FL 32611
Physical Address:
1600 SW ARCHER RD
MSB PG-05A
GAINESVILLE FL 326103003

Dr. Cooper-DeHoff is a Associate Professor in the Department of Pharmacotherapy and Translational Research, and the Department of Pharmaceutics in the College of Pharmacy, and in the Division of Cardiovascular Medicine, College of Medicine at the University of Florida.

Accomplishments:
  • Fellow
    2014 · American College of Clinical Pharmacy
  • Research Featured
    2009 · American Society of Hypertension
  • Clinical Science Award
    2008 · Consortium for Southeastern Hypertension Control
  • Fellow
    2007 · American Heart Association
Research Summary:

Dr. Cooper-DeHoff’s research interests include hypertension, metabolic syndrome, diabetes, coronary artery disease and antihypertensive drug-induced diabetes, as well as the impact of pharmacogenetic variations in each of these areas. She’s also the lead investigator of the hypertension working group within the Patient-Centered Outcomes Research Institute-funded Clinical Data Research Network — OneFlorida — which affords trainees the opportunity to work at an epidemiologic level to explore population-level questions about hypertension. Trainees also learn about the complexities and benefits of working in electronic health record data at the research level. Dr. Cooper-DeHoff’s resistant hypertension research includes mass spectrometry analysis of antihypertensive drugs, metabolomics and gut microbiota available for analysis.

Publications:
Grants:
  • Jun 2022 ACTIVE
    Genetic Associations of Ischemic Heart Disease and Symptoms Among Diverse Postmenopausal Women
    NATL INST OF HLTH NIA · Co-Investigator
  • Apr 2020 – Mar 2021
    Use of Real-World Evidence to Characterize Patients with Uncontrolled Hypertension
    YALE CENTER FOR OUTCOMES RESEARCH & EVAL · Co-Investigator
  • May 2019 – Jul 2021
    Research Collaboration Agreement for Data Transfer and Use of Limited Data Set
    DUKE UNIVERSITY · Principal Investigator
  • Nov 2018 – Nov 2019
    Cardiovascular Health Collaborative Research Group
    PATIENT-CENTERED OUTCOMES RES INST · Principal Investigator
  • Sep 2018 ACTIVE
    Using PCORnet to Compare Blood Pressure Control Strategies
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jul 2018 ACTIVE
    Advancing Personalized Hypertension Care through Big Data Science
    NATL INST OF HLTH NHLBI · Other
  • Jun 2018 ACTIVE
    INTEGRATIVE DATA APPROCACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTION
    NATL INST OF HLTH NHLBI · Other
  • Sep 2017 ACTIVE
    Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
    US ARMY MED RES ACQUISITION · Co-Investigator
  • Jan 2017 – Aug 2018
    PCORnet Cardiovascular Health Collaborative Research Group
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Oct 2015 – Mar 2019
    OneFlorida Clinical Research Consortium Phase II
    PATIENT-CENTERED OUTCOMES RES INST · Project Manager
  • May 2015 – Apr 2016
    Optimizing Rural Health Clinic Infrastructure to Maximize BP Control (OPTI-BP)
    FL HLTH EQUITY RESEARCH INST · Principal Investigator
  • Apr 2015 – Jun 2021
    Clinical and Translational Science Institute (CTSI)
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Aug 2010 – Jul 2017
    Pharmacogenomic Evaluation of Antihypertensive Responses.
    NATL INST OF HLTH NIGMS · Co-Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Project Manager
Patents:
  • Published April 2004
    Combination Drug Therapy for Treating Hypertension
    #US 2005-0032784 A1
  • Issued November 1999
    Method & System For Interactive Prescription and Distribution of Perscriptions in Conducting Medical Studies (CON)
    #5,991,731
Education:
  • 2007
    M.S.
    University of Florida
  • 1986
    Pharm.D.
    University of California at San Fransisco
Julio D Duarte

Julio D Duarte Pharm.D., Ph.D., FAHA

Assistant Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-8132
Mailing Address:
PO Box 100486
GAINESVILLE FL 32610
Physical Address:
1600 SW ARCHER RD RM PG 21
GAINESVILLE FL 32610

Julio Duarte is an assistant professor in the Department of Pharmacotherapy and Translational Research and the Center for Pharmacogenomics and Precision Medicine. He received his Pharm.D. as well as his Ph.D. in clinical pharmaceutical sciences from the University of Florida. He was Assistant Professor of Pharmacy Practice at the University of Illinois at Chicago (UIC) until coming to UF in 2015. While at UIC, Dr. Duarte was the Director of the Pharmacogenomics Laboratory and Co-Director of the University of Illinois Hospital Personalized Medicine Program. Dr. Duarte has served as a reviewer for both NIH and U.S Department of Defense study sections. He is also an elected fellow of the American Heart Association and has received awards for his research from both UIC and UF. In 2021, Dr. Duarte began serving as Associate Graduate Program Director of the Clinical Pharmaceutical Sciences Program and Associate Director of the Center for Pharmacogenomics and Precision Medicine.

Accomplishments:
  • Outstanding Clinical Research Award
    2017 · University of Florida College of Pharmacy
  • Fellow
    2017 · American Heart Association
  • Hans Vahlteich Research Scholar
    2013 · College of Pharmacy, University of Illinois at Chicago
Research Summary:

Dr. Duarte’s research primarily focuses on: (1) the biological mechanisms underlying pulmonary hypertension development in patients with with left heart failure, and (2) the clinical implementation of pharmacogenetic testing, particularly in medically underserved patient populations. His NIH-funded laboratory conducts translational research attempting to discover genomic predictors of drug response, as well as using genomics and transcriptomics to identify novel targets for future drug development.

Publications:
Grants:
  • Jun 2022 ACTIVE
    Genetic Associations of Ischemic Heart Disease and Symptoms Among Diverse Postmenopausal Women
    NATL INST OF HLTH NIA · Co-Investigator
  • Sep 2021 ACTIVE
    Preemptive pharmacogenetic testing in medically underserved populations
    NATL INST OF HLTH NHGRI · Principal Investigator
  • Jul 2021 ACTIVE
    Using Artificial Intelligence to Identify Patients Most Likely to Benefit from Preemptive Pharmacogenetic Testing
    UF HEALTH SHANDS HOSPITAL · Principal Investigator
  • Jul 2020 – Mar 2022
    Together Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Project Manager
  • Nov 2015 – Mar 2020
    Improving treatment personalization for pulmonary hypertension associated with diastolic heart failure
    NATL INST OF HLTH NIGMS · Principal Investigator
Education:
  • 2010
    Ph.D.
    University of Florida
  • 2006
    Pharm.D.
    University of Florida
Jatinder Lamba

Jatinder Lamba Ph.D., M.Sc.

Professor, Graduate Coordinator And The Frank A. Duckworth Eminent Scholar Chair
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-6425
Mailing Address:
PO Box 100486
GAINESVILLE FL 32610
Physical Address:
1333 CENTER DR
P1-31 HSC BUILDING
GAINESVILLE FL 326103006

Dr. Jatinder Lamba is currently Professor in the Department of Pharmacotherapy and Translational Research. She did her post-doctoral training at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to joining University of Florida, she was an Associate Professor at University of Minnesota, Department of Experimental and Clinical Pharmacology, College of Pharmacy and the Director of the Pathway driven Pharmacogenomics; University of Minnesota Alliance (PUMA) Institute of Personalized Medicine.

Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. The long-term goal of her research is to move pharmacogenetic testing into the clinical setting to improve safety and efficacy of drug therapy. Dr. Lamba’s research on pharmacogenomics of anti-leukemic agents has been funded by NIH/NCI since 2008. Specifically, her current NCI funded R01 focuses on pharmacogenomics/ epigenomics of cytarabine (ara-C), a nucleoside analog that is the backbone of anti-leukemia chemotherapy in pediatric AML patients. Her group is working on developing algorithms to incorporate pharmacogenomics/epigenomic markers with other prognostic factors to advance precision medicine in oncology. Identification of such patients upfront will provide opportunity to tailor the initial chemotherapy to achieve maximum benefit.

Dr. Lamba’s lab is the first one to identify genetic polymorphisms in CD33 gene that are predictive of response to CD33 targeted agents in AML. These results hold promise in utilizing preemptive genotype to select patients most likely to benefit from CD33-directed therapy such as gemtuzumab ozogamicin in treating AML. Previous work on CD33 genomics was funded by NCI and more in-depth characterization of CD33 as AML therapeutic target is funded by a recent award from leukemia Lymphoma Society.

Given a critical gap of our understanding in metabolic dysregulation in AML, Dr. Lamba’s group is focused understanding the metabolomics differences and biomarkers of prognostic significance in pediatric AML. Dr. Lamba’s recent work is focused towards utilizing transcriptomics to build and refine leukemic stem cell signatures and AML drug response signatures of prognostic and predictive value in AML.

Dr. Lamba has served as chair of Pharmacogenomics SIG at AACP (2013) and is currently vice-chair of Pharmacogenomics focus group with AAPS. She has served as a grant reviewer for numerous NIH study sections and has reviewed grants for international agencies as Italian Ministry of Health. She has published more than 90 research articles in peer-reviewed journals and is on the editorial boards of Leukemia and Lymphoma, Pharmacogenomics and Frontiers in Pharmacogenomics and genomics, JCMM. Dr. Lamba is currently Professor in College of Pharmacy and is also Graduate Program coordinator for PTR department. Dr. Lamba is very committed towards training of future generation of scientist. She has trained 6 Ph. D students, 5 Post-doctoral fellows several Pharm D students and 3 hematology-oncology fellows and several under-graduate students including minority and underrepresented students.

Publications:
Grants:
  • Apr 2022 ACTIVE
    Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury
    FL DEPT OF HLTH LIVE LIKE BELLA · Other
  • Jul 2021 ACTIVE
    Genomics of AML Prognosis
    NATL INST OF HLTH NCI · Principal Investigator
  • Jul 2021 ACTIVE
    Transcriptomic and pharmacogenetic scores to guide therapy in pediatric AML
    AMER CANCER SOC · Principal Investigator
  • Sep 2020 – Aug 2021
    Pharmacogenomic Drivers of Efficacy in Anti-CD33 Immunotherapeutic Treatment Strategies
    AMER FOU FOR PHARM EDU · Other
  • Sep 2020 – Aug 2021
    AFPE Fellowship: Rho Chi -AFPE Graduate Fellowship
    AMER FOU FOR PHARM EDU · Other
  • Aug 2020 – Jul 2021
    Pharmacokinetics and Pharmacogenomics of Pediatric Chemotherapeutics
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jan 2020 ACTIVE
    Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or Lymphoma
    CHILDRENS HOSP OF ORANGE COUNTY · Principal Investigator
  • Jul 2019 ACTIVE
    Personalizing CD33-directed Immunotherapy for Pediatric AML
    LEUKEMIA & LYMPHOMA SOC · Principal Investigator
  • Jul 2019 – Jun 2020
    Personalizing CD33-directed immunotherapy for pediatric AML
    CHILDRENS ONCOLOGY GROUP · Principal Investigator
  • Apr 2019 – Mar 2022
    Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
    FL DEPT OF HLTH LIVE LIKE BELLA · Principal Investigator
  • Jun 2018 – May 2021
    OR-DRPD-ROD2018: Development of Leukemia-Oncotype Prototype CARS (Cytarabine AML Response Score) for Prediction of Relapse Risk in AML
    UF RESEARCH · Principal Investigator
  • Feb 2018 – Jan 2019
    Impact of CD33 Genetics on Clinical Outcome in Pediatric AML Patients Treated on AAML0531 Clinical Trial
    CHILDRENS ONCOLOGY GROUP · Principal Investigator
  • Dec 2016 – Jan 2020
    Multiple Sponsors
    MULTIPLE SPONSORS · Principal Investigator
  • Jan 2015 – Jan 2016
    DNA ISOLATION/GENOTYPING COLLABORATION
    UNIV OF MINNESOTA TWIN CITIES · Principal Investigator
  • Sep 2014 – Apr 2020
    Pharmacogenomics of Ara-C in AML
    NATL INST OF HLTH NCI · Principal Investigator
  • Jul 2014 – Dec 2015
    Impact of genetic variation on response to GO therapy in COG-AML clinical trials
    NATL INST OF HLTH NCI · Principal Investigator
Education:
  • 2000
    Ph.D.
    Postgraduate Institute of Medical Education and Research
  • 1994
    M.Sc.
    Postgraduate Institute of Medical Education and Research
  • 1992
    B.Sc.
    Panjab University
David R Nelson

David R Nelson M.D.

Senior Vice President For Health Affairs, UF & President, UF Health
Department: Senior Vice President for Health Affairs
Phone: (352) 733-1700
Mailing Address:
PO Box 100014
GAINESVILLE FL 32610
Physical Address:
J277 JHMHC
GAINESVILLE FL 32611

David R. Nelson, M.D., was appointed senior vice president for health affairs at the University of Florida and president of UF Health in April 2019. Dr. Nelson oversees operations for all components of UF Health, the university’s academic health center, with campuses in Gainesville and Jacksonville. This includes six health science colleges, nine interdisciplinary research centers, three hospital systems and more than 100 physician practices. He is committed to strategically position UF Health for smart growth; enhancing operations; supporting faculty, staff and students; and fostering a diverse, inclusive and equitable community. He also has continued to explore ways to optimize the speed of translation of research, bringing science to the bedside and to the community to improve patient care for individuals and populations. A professor of medicine and an expert in liver disease, Dr. Nelson’s record of academic achievement includes more than $100 million in research funding, more than 200 publications and multiple leadership roles in his area of expertise. He has co-authored the U.S. treatment guidelines for hepatitis C, the Clinical Pharmacogenetics Implementation Consortium guidelines for the use of genomic-guided hepatitis C (HCV) therapy, and represented the United States on the World Health Organization HCV guidelines committee. As a principal investigator on basic science, translational research and training grants, he developed an international real world data network (HCV-TARGET), a collaboration between clinician investigators, the pharmaceutical industry and the Food and Drug Administration (FDA). This transformed drug development pathways and led to faster and safer development of HCV therapies, resulting in his recognition by the FDA with the Regulatory Science Excellence Honor in 2018. In 2013, he was recognized for one of the Clinical Research Forum’s Top 10 Clinical Research Achievements and in 2014, he received the Association of American Medical Colleges’ Learning Health System Research Champion Award. He has continuously been recognized as one of America’s top physicians/gastroenterologists and has been the recipient of multiple exemplary teaching awards, an outstanding alumnus award from his medical school, a UF Research Foundation Professorship Award and a UF Term Professorship Award.

Dr. Nelson received his undergraduate degree from Dartmouth College and his medical degree from State University of New York Upstate University in Syracuse, New York. He completed a residency in internal medicine at the University of Massachusetts and obtained fellowship training in gastroenterology and hepatology at UF.

Certifications:
  • Gastroenterology
    American Board of Gastroenterology
  • Internal Medicine
    American Board of Internal Medicine
  • Transplant Hepatology
    American Board of Internal Medicine
Specialties:
  • Medicine
Subspecialties:
  • Gastroenterology
  • Transplant Hepatology
Clinical Interests:
  • Cirrhosis
  • Hepatitis C
  • Liver cancer – hepatocellular carcinoma
  • Liver disease
  • Liver disease – resources
  • Liver transplant
Publications:
Grants:
  • May 2020 ACTIVE
    COVID-19: Higher Education Emergency Relief Fund-Institutional Portion
    US DEPT OF EDUCATION · Project Manager
  • Sep 2018 ACTIVE
    Sparking Advancements in Genomic Medicine?
    NATL INST OF HLTH NHGRI · Co-Investigator
  • May 2018 ACTIVE
    Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
    NATL INST OF HLTH NIDA · Other
  • Apr 2018 – Jul 2019
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Principal Investigator
  • Apr 2018 – Oct 2018
    Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
    UNIV OF ALABAMA BIRMINGHAM · Co-Investigator
  • Nov 2017 – Oct 2018
    Safety of Direct Acting Antiviral Medications for Hepatitis C
    KAISER FOU RESEARCH INSTITUTE · Co-Investigator
  • Apr 2017 – Jun 2021
    OoR CTSI Institutional Matching Support
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Apr 2017 – Jun 2020
    COM CTSI Institutional Matching Support Year 3-4
    FL CLINICAL PRACTICE ASSO · Principal Investigator
  • Apr 2017 – Mar 2018
    The National Dental PBRN FY18
    UNIV OF ALABAMA BIRMINGHAM · Co-Investigator
  • Apr 2017 – Mar 2018
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Principal Investigator
  • Mar 2017 – Mar 2021
    A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
    ABBVIE · Principal Investigator
  • Mar 2017 – Mar 2021
    A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
    ABBVIE · Principal Investigator
  • Aug 2016 – Jul 2017
    The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
    UNIV OF NORTH CAROLINA CHAPEL HILL · Principal Investigator
  • Jul 2016 ACTIVE
    Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
    NATL INST OF HLTH NIGMS · Co-Investigator
  • May 2016 – Aug 2021
    THE PRIORITIZE STUDY: A PRAGMATIC, RANDOMIZED STUDY OF ORAL REGIMENS FOR HEPATITIS C: TRANSFORMING DECISION-MAKING FOR..
    Merck Sharp & Dohme · Principal Investigator
  • Apr 2016 – Mar 2017
    TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE HEALTH ,
    NATL INST OF HLTH NCATS · Principal Investigator
  • Apr 2016 – Mar 2017
    TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TOIMPROVE HEALTH
    NATL INST OF HLTH NCATS · Project Manager
  • Jan 2016 – Apr 2017
    The National Dental PBRN
    UNIV OF ALABAMA BIRMINGHAM · Project Manager
  • Jan 2016 – Mar 2022
    Prioritize Study
    PATIENT-CENTERED OUTCOMES RES INST · Principal Investigator
  • Dec 2015 – Dec 2018
    A SINGLE ARM OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT-493/ABT-530 IN RENALLY IMPAIRED ADULTS WITH…
    ABBVIE · Principal Investigator
  • Sep 2015 – Sep 2018
    An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Subjects with Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)
    ABBVIE · Principal Investigator
  • Aug 2015 – Jul 2018
    Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
    UNIV OF NORTH CAROLINA CHAPEL HILL · Principal Investigator
  • Aug 2015 – Jul 2016
    Validation of an Observer Reported Outcome (ObsRO) Measure of Home Functionality in Children with Pyruvate Dehydrogenase Complex Deficiency (PDCD)
    UNITED MITOCHONDRIAL DISEASE FOU · Project Manager
  • Jul 2015 ACTIVE
    Florida Academic Cancer Center Alliance Seed Grants
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Jun 2015 – Jun 2023
    A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials"
    GILEAD SCIENCES · Principal Investigator
  • Jun 2015 ACTIVE
    A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials"
    GILEAD SCIENCES · Principal Investigator
  • Jun 2015 – Dec 2016
    Evaluation of Baseline HCV Resistance mutations in Genotype1 patients initiating tretamnent in real-world settings
    JANSSEN SERVICES · Principal Investigator
  • May 2015 – Mar 2016
    UF CTSI NRSA Training Core
    NATL INST OF HLTH · Project Manager
  • May 2015 – Mar 2016
    Together: Transforming and Translating Discovery to Improve Health
    NATL INST OF HLTH NCATS · Principal Investigator
  • Apr 2015 – Jun 2021
    Clinical and Translational Science Institute (CTSI)
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Feb 2015 – Feb 2018
    A single arm, open label study to evaluate the efficacy and satety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1,2,4,5 or 6 infection and compensated Cirrhosis
    ABBVIE · Principal Investigator
  • Nov 2014 – Jun 2020
    PAYROLL OPERATING ACCOUNT
    UNIV OF FLORIDA · Principal Investigator
  • Jul 2014 – Oct 2017
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Jun 2014 – Sep 2018
    BMS AI444-257 A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Mar 2014 – Jun 2022
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    GILEAD SCIENCES · Principal Investigator
  • Feb 2014 – Feb 2017
    MK-5172 'A PHASE II/II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH HCV AND CHRONIC KIDNEY DISEASE'
    Merck Sharp & Dohme · Principal Investigator
  • Feb 2014 – Feb 2017
    IDX-03YF '3-YEAR, Observ Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, DAA'
    IDENIX PHARMACEUTICALS · Principal Investigator
  • Feb 2014 – Feb 2016
    AI444-218 'A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Na?ve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection'
    BRISTOL MYERS SQUIBB CO PHARM RES INST · Principal Investigator
  • Dec 2013 – Dec 2016
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    JANSSEN SERVICES · Principal Investigator
  • Oct 2013 – Dec 2020
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    ABBVIE · Principal Investigator
  • Oct 2013 – Oct 2016
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
    NOVARTIS PHARMA AG · Principal Investigator
  • Oct 2013 – Oct 2016
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
    ROCHE MOLECULAR SYSTEMS · Principal Investigator
  • Sep 2013 – Sep 2016
    AbbVie M13-102 'A Follow-up Study to Assess Resistance and Durability of Response to AbbVie DAA Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the TX of Chronic HCV Infection' (AbbVie Protocol M13-102)
    ABBVIE · Principal Investigator
  • Jul 2013 – Dec 2019
    Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
    US ARMY MED RES ACQUISITION · Project Manager
  • Jun 2013 – Sep 2018
    Genomic Medicine Implementation: The Personalized Medicine Program
    NATL INST OF HLTH NHGRI · Project Manager
  • Apr 2013 – Mar 2016
    GS-US-337-0108 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir FDC ? RBV for 8 Wks and Sofosbuvir/Ledipasvir FDC Combo for 12 Wks in Tx-Na?ve Subjects with Chronic Genotype 1 HCV'
    GILEAD SCIENCES · Principal Investigator
  • Apr 2013 – Apr 2016
    A Randomized Study to Evaluate the Safety and Efficacy of IDX179 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection'
    IDENIX PHARMACEUTICALS · Principal Investigator
  • Jan 2013 – Jan 2016
    BI 201335 and BI 207127 Combination Therapy in Treatment -Naive HCV Patients
    BOEHRINGER INGELHEIM PHARM INC · Principal Investigator
  • Dec 2012 – Dec 2015
    GS-US-337-0109 'G??A Phase 3, Multicenter, Randomized, Open-Label Study for Efficacy and Safety of Sofosbuvir/GS-5885 FDC -? Ribavirin for 12 & 24 Weeks in Treatment-Experienced Subjects w/Chronic Genotype 1 HCV InfectionG??
    GILEAD SCIENCES · Principal Investigator
  • Nov 2012 – Nov 2015
    Nelson Abbott M13-099 'A Randomized, Open-label Study of ABT 450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 W RBV in Geno 1 (HCV) Infection and Human Cirrhosis (TURQUOISE-II)'
    ABBVIE · Principal Investigator
  • Oct 2012 – Oct 2015
    Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
    ABBVIE · Principal Investigator
  • Oct 2012 – Dec 2019
    HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
    Merck Sharp & Dohme · Principal Investigator
  • Sep 2012 – Sep 2015
    GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
    GILEAD SCIENCES · Principal Investigator
  • Mar 2012 – Mar 2016
    An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
    ABBOTT LABORATORIES · Principal Investigator
  • Nov 2011 – Sep 2018
    GS-US-248-0123 A Long Term Follow-up Registry Study of Subjects Who DidNot Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    GILEAD SCIENCES · Principal Investigator
  • Nov 2011 – Nov 2019
    GS-US-248-0122, A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    GILEAD SCIENCES · Principal Investigator
  • Nov 2011 – Nov 2017
    'A PHASE 3B STUDY OF 2 TX DURATIONS OF TELAPREVIR, PEGASYS, AND COPEGUS IN TREATMENT-NAIVE AND PRIOR RELAPSER SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND IL28B CC GENOTYPE'
    VERTEX PHARMACEUTICALS · Principal Investigator
  • Oct 2011 ACTIVE
    HCV-TARGET Primary Operating Project with subprojects
    UF DIV OF SPONSORED RESEARCH · Principal Investigator
  • Sep 2011 ACTIVE
    HCV TARGET: Hepatitis C Therapeutic Registry and ResearchNetwork
    KADMON · Principal Investigator
  • Sep 2011 – Sep 2017
    M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
    ABBVIE · Principal Investigator
  • Jun 2011 – Jun 2017
    'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Dec 2010 – Dec 2016
    GS-US-196-0123
    GILEAD SCIENCES · Principal Investigator
  • Aug 2010 – Aug 2016
    BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Mar 2010 – Mar 2016
    VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
    VERTEX PHARMACEUTICALS · Principal Investigator
  • Mar 2010 ACTIVE
    OPERATING ACCOUNT: HEPATOLOGY
    UNIV OF FLORIDA · Principal Investigator
  • Jan 2010 – Jan 2020
    INDUSTRY SPONSORED CLINICAL TRIAL OPERATING ACCOUNT
    UNIV OF FLORIDA · Principal Investigator
  • Jul 2007 – Aug 2016
    Clinical and Translational Science Institute
    UF RESEARCH FOU · Principal Investigator
  • Jul 2006 – Dec 2020
    21st Century Research & Economic Development Investment Program (REDIP)
    STATE UNIV SYS OF FL BOARD OF GOVERNORS · Project Manager
  • Mar 2005 – Feb 2020
    Lawton Family Liver Research – UFF Fund #008386
    UF FOUNDATION · Principal Investigator
  • Mar 2005 – Feb 2020
    Res & Dev Gastroenterology – UFF Fund #002739
    UF FOUNDATION · Principal Investigator
Education:
  • 1996
    Fellowship – Gastroenterology
    University of Florida
  • 1993
    Residency – Internal Medicine
    University of Massachusetts
  • 1990
    Medical Degree
    SUNY Health Science Center
Danxin Wang

Danxin Wang M.D., Ph.D.

Associate Professor
Department: Pharmacotherapy & Translational Research
Phone: (352) 273-7673
Mailing Address:
PO Box 100486
GAINESVILLE FL 32610
Physical Address:
1345 CENTER DRIVE MSB ROOM PG-05B
GAINESVILLE FL 326100001

Dr. Wang received her MD degree from Fudan University Medical School and her Ph.D from the Academy of Military Medical Science in Beijing. She did postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics and Associate Director of Center for Pharmacogenomics prior to joining the University of Florida.

Dr. Wang’s research interests are the discovery of genetic biomarkers for personalized drug therapy. She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases and drug dependence. Some of these functional variants are currently included in biomarker testing panels to predict drug response.

Funded by NIH R01 and R35 awards, Dr. Wang’s current research is to understand factors controlling the expression of cytochrome P450 drug metabolizing enzymes (CYPs) in the liver. Using recently developed cutting edge functional genetics/genomics approaches, the research will focus on understanding what genetic, epigenetic and non-genetic factors may contribute to CYPs variability, with the goal to identify biomarker predicting enzyme activity of CYPs for guiding personalized drug therapy.

Dr. Wang has served as an Associate Editor of “European Journal of Pharmaceutical Sciences” and was on editorial Board of “Journal of Pharmacogenomics and Pharmacoproteomics”. She has also served as grant reviewer for NIH.

Research Interests:
  • Drug Metabolism
  • Gene expression
  • Pharmacogenetics
  • Pharmacogenomics
Publications: